Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA068255-02
Application #
2112156
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1995-09-15
Project End
2000-08-31
Budget Start
1996-09-01
Budget End
1997-08-31
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost

  Institution

Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195

  Publications

Disis, Mary L; Shiota, Faith M; McNeel, Douglas G et al. (2003) Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens. Immunobiology 207:179-86
Disis, M L; Schiffman, K (2001) Cancer vaccines targeting the HER2/neu oncogenic protein. Semin Oncol 28:12-20
Ward, R L; Hawkins, N J; Coomber, D et al. (1999) Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. Hum Immunol 60:510-5
Disis, M L; Cheever, M A (1998) HER-2/neu oncogenic protein: issues in vaccine development. Crit Rev Immunol 18:37-45
Disis, M L; Shiota, F M; Cheever, M A (1998) Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens. Immunology 93:192-9
Disis, M L; Cheever, M A (1997) HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 71:343-71